P110_Dosage, benefits & legal status
Also known as P110-TAT, TAT-P110, Drp1-Fis1 inhibitor peptide, DLLPRGS, P110 peptide
A research peptide that blocks one route to mitochondrial fragmentation, tested only in cells and animals.
Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is P110?
Plain language first. The technical label stays, but it never stands alone.Overview
It stops the kind of mitochondrial splitting that happens under stress while leaving everyday splitting alone, and it has lengthened survival or protected neurons in mouse models of Huntington's, ALS, Alzheimer's and Parkinson's disease. It has never been given to a human being. The form sold as a research reagent is a 20-residue version fused to a cell-entry sequence.
P110 is a seven-amino-acid peptide (DLLPRGS) copied from the human protein Drp1, designed in Daria Mochly-Rosen's laboratory at Stanford to block Drp1 from docking with its partner Fis1.
What it's used for
A laboratory reagent for studying mitochondrial fission. No human use, dose, safety data or trial exists.
How does P110 work?
What it does in the body, and where.P110 blocks one specific handshake inside the mitochondrial splitting machinery: Drp1 meeting Fis1.
- 01Copied from Drp1 itselfThe seven residues match Drp1 positions 49 to 55 (DLLPRGT) with the last changed to the matching Fis1 residue, giving DLLPRGS. The peptide occupies a groove on Drp1 so Fis1 cannot dock.
- 02Selective for stress-driven fissionDrp1-Fis1 binding rises under stress; Drp1-Mff binding runs all the time. Blocking Fis1 cut fragmentation and cell death in stressed cells while leaving baseline fission untouched.
- 03Why the selectivity mattersThe same lab's peptide against Drp1-Mff (P259) lowered brain ATP by about 30%, slowed healthy mice and shortened survival in Huntington's mice. Blocking fission wholesale is harmful; the claim for P110 rests entirely on blocking only one partner.
A schematic of the compound's mechanism, not a diagnostic image.
What else is it used for?
Each group carries its own evidence level.Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
Neurodegeneration in mice
Early research- Animal studyHuntington's model: after 8 weeks of continuous infusion, 1 of 12 treated mice had died by 13 weeks against 6 of 12 on a control peptide, with motor function near wild-type.
- Animal studyALS model: median survival 132 days against 122 on vehicle when started at symptom onset, a ten-day gain.
- Animal studyAlzheimer's model: lower brain amyloid, restored ATP and better memory tests after three months. Parkinson's (MPTP) model: more dopamine neurons survived, but striatal dopamine was not significantly higher.
- No dataNo human has ever received P110. There is no trial, no dose, no pharmacokinetic data and no safety data in people.
Safety signals in animals
Early research- Animal studyHealthy mice infused for five months showed no toxicity or behavioural change, and body weight was unaffected across studies. No formal toxicology study has been run.
- Animal studyA 2018 report found treated mice had reduced maximal exercise capacity, consistent with the Drp1-Fis1 route being needed for exercise-related fission. Blocking the neighbouring Drp1-Mff route was clearly harmful.
Three sequences circulate. DLLPRGS is P110. DLLPRGT is the parent stretch of human Drp1, not the peptide. DLLRPGT, found in an otherwise good review, is a transposition error. Vials labelled "P110" from reagent suppliers contain the 20-residue TAT-fused construct (YGRKKRRQRRRGGDLLPRGS), not the bare heptapeptide; the molecular weights give it away. The 3 mg/kg/day figure is a continuous infusion rate from a surgically implanted pump, not an injectable dose, and nothing supports scaling it to a person. "Inhibits mitochondrial fission" without the Drp1-Fis1 qualifier misstates the whole claim, since its own developers showed general fission blockade to be harmful. "P110" also names the PI3K catalytic subunit, so most search hits are unrelated.
At a glance
Four things to know about P110
Evidence
Category
Longevity and energy
Common vial
Varies
Half-life
Nothing published
How much, and do you cycle it?
The range, and whether you take breaks.No human dose; 1.5 to 3 mg/kg/day by continuous pump in mice, continuous infusion in animals. No established pattern No range
No human study exists. Animal studies infused it continuously for 8 weeks to 5 months.
Nothing publishedNo figure
No pharmacokinetic study of P110 or its TAT-fused form exists in any species. A secondary review estimates about one hour without citing a measurement. The animal studies relied on continuous pumps and so never needed to answer the question.
You can compare this against the whole library to see where it sits.
How do I dose and price it?
Enter your vial and your dose. Pick a mix. We show the draw and the cost.The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.
Choose your mix
Measuring the water1 mL = one full 100-unit syringe.
How do you store it?
Before mixing, and after.Dry powder in the freezer or fridge. Once mixed, fridge, and use within about a month.
Unmixed lyophilized P110 keeps for a long time cold. Once you add water the clock starts: most reconstituted vials hold up for roughly 28 to 30 days at fridge temperature. Keep it out of light, and do not freeze it after mixing.
What are the side effects and cautions?
Known cautions and warnings for this compound.Solubility, computed: 57% charged residues, 43% hydrophobic. Water usually sufficient.
A first-pass rule from peptide manufacturers' guidance. It does not account for disulfide bridges, salt form or how the powder was dried, and it predicts what should be easy rather than what will happen in your vial.
Who should avoid it
- Everyone, in the sense that no human has taken it and there is no basis for anyone to be the first
- Pregnancy or breastfeeding
- Anyone with a prescription medicine, since no interaction data exist
Stop and get help
- Spreading hives, swelling of the face or throat, or trouble breathing
- Redness, heat, or pus at an injection site
- Anything unusual, since there is no known safety profile to compare it against
Common effects
- Unknown. No human has received it
- In mice, months of infusion at 3 mg/kg/day changed neither body weight nor behaviour in healthy animals
- One study reported reduced maximal exercise capacity in treated mice, suggesting the Drp1-Fis1 route is needed for exercise-related fission
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is P110 approved?
And where the numbers on this page come from.No. P110 is not approved for any use, anywhere. It is sold labelled for laboratory research only, and there is no legal route to buy it for human use.
- Approval statusResearch only
- RouteUnder the skin by implanted pump (animal studies only)
- Checked10 October 2026
- DoseFrom research and community reports. No regulator has reviewed this dose.
- Vial sizeFrom what vendors typically list; not a recommendation.
- SourcesRios L et al., Nature Communications 2023, allosteric site on Drp1Qi X, Qvit N, Su YC, Mochly-Rosen D, Journal of Cell Science 2013, original characterisationGuo X et al., Journal of Clinical Investigation 2013, Huntington's disease modelJoshi AU et al., EMBO Molecular Medicine 2018, ALS modelJoshi AU et al., Oncotarget 2018, Alzheimer's disease model (PMID 29464060)Filichia E et al., Scientific Reports 2016, MPTP Parkinson's modelKornfeld OS et al., Scientific Reports 2018, the Drp1-Mff peptide P259Alzheimer's Drug Discovery Foundation, Drp1 inhibitors update (rev. 13 Mar 2026)UniProt O00429, human Drp1 (DNM1L)Tocris (Bio-Techne), P110 catalogue 6897
What has happened recently
Not approved anywhere and not in any clinical trial. Two independent reviews of Drp1 inhibitors (Alzheimer's Drug Discovery Foundation, latest March 2026) state that P110 has not been tested in humans and that no trial is underway or planned. It is a composition of matter under Stanford patents licensed to Mitoconix Bio, whose lead compound for Huntington's disease was described as preclinical in 2017; whether that compound is P110 has not been confirmed.
You can compare this against the whole library, or read how to check a seller.
What else is like P110?
Others in Longevity and energy, side by side.If you're weighing P110, it's worth reading SHLP2, SHLP6, and Urolithin A in the same class.
A research peptide that blocks one route to mitochondrial fragmentation, tested only in cells and animals.
- Dose
- No human dose; 1.5 to 3 mg/kg/day by continuous pump in mice
- How often
- Continuous infusion in animals
A mitochondrial peptide with real published biology and no human dosing behind it.
- Dose
- Research only
- How often
- Not established
The sibling of SHLP2, and the one reported to shut blood vessel growth down.
- Dose
- Research only
- How often
- Not established
The mitophagy supplement with two real trials, both of which missed.
- Dose
- 500 up to 1,000 mg per day
- How often
- Daily
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
- Rios L et al., Nature Communications 2023, allosteric site on Drp1(2023)States the P110 heptapeptide is DLLPRGS and the TAT-fused construct YGRKKRRQRRRGGDLLPRGS; maps the binding groove on Drp1; shows P110 blocks the stress-induced Drp1-Fis1 interaction without changing Drp1-Mff.
- Qi X, Qvit N, Su YC, Mochly-Rosen D, Journal of Cell Science 2013, original characterisation(2013)In a cell model of Parkinson's disease and primary dopaminergic neurons, P110 reduced mitochondrial fragmentation, ROS and cell death with minimal effect at baseline.
- Guo X et al., Journal of Clinical Investigation 2013, Huntington's disease model(2013)R6/2 mice, 3 mg/kg/day by subcutaneous osmotic pump for 8 weeks: motor deficits reduced, 1 of 12 treated mice dead by 13 weeks against 6 of 12 on the control peptide, Huntingtin aggregates down about 60%.
- Joshi AU et al., EMBO Molecular Medicine 2018, ALS model(2018)SOD1-G93A mice, 3 mg/kg/day by pump from symptom onset: median survival 132 days against 122 days on vehicle (p=0.007). Five months of infusion in healthy mice produced no toxicity or behavioural change.
- Joshi AU et al., Oncotarget 2018, Alzheimer's disease model (PMID 29464060)(2018)5XFAD mice, 3 mg/kg/day by pump for about three months: lower brain amyloid-beta, restored ATP, less lipid peroxidation, better nest building and memory tests. The paper's methods say 3 mg/kg/day and its results say 3 mg/day.
- Filichia E et al., Scientific Reports 2016, MPTP Parkinson's model(2016)Mice, 1.5 mg/kg/day by pump started 16 hours before MPTP: fewer dopamine neurons lost and better movement scores, but striatal dopamine levels were not significantly different from untreated controls.
- Kornfeld OS et al., Scientific Reports 2018, the Drp1-Mff peptide P259(2018)Blocking the other Drp1 partner at the same dose lowered brain ATP about 30%, reduced activity in healthy mice and shortened survival in Huntington's mice. The authors conclude fission must be targeted selectively.
- Alzheimer's Drug Discovery Foundation, Drp1 inhibitors update (rev. 13 Mar 2026)(2026)P110 has not been tested in humans; no clinical or observational studies exist; no Drp1 inhibitor has been formulated for clinical use. Reports no oral bioavailability and protease susceptibility.
- UniProt O00429, human Drp1 (DNM1L)(2026)Residues 49 to 55 read DLLPRGT, the parent sequence P110 was designed from.
- Tocris (Bio-Techne), P110 catalogue 6897(2026)Sold under the bare name P110 but with molecular weight 2,411.8, matching the TAT-fused 20-residue construct rather than the 771 Da heptapeptide.